Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABEONASDAQ:ABUSNASDAQ:ARCTNASDAQ:NATRNASDAQ:THTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$5.75-2.4%$6.05$3.93▼$7.32$301.31M1.51697,142 shs750,706 shsABUSArbutus Biopharma$3.14-3.1%$3.34$2.71▼$4.73$620.55M1.2959,688 shs608,992 shsARCTArcturus Therapeutics$13.36-3.0%$12.48$8.04▼$25.88$373.72M2.27421,219 shs428,993 shsNATRNature's Sunshine Products$16.02+2.8%$14.37$10.81▼$18.06$287.84M1.1451,232 shs168,196 shsTHTXTheratechnologies$3.17-0.9%$2.62$1.12▼$3.20$147.14M0.55880,339 shs4.94 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics-2.61%+1.23%-14.69%+33.10%+26.65%ABUSArbutus Biopharma-2.94%+1.62%-9.77%+9.03%+0.64%ARCTArcturus Therapeutics-2.02%+2.69%+4.46%+49.94%-37.72%NATRNature's Sunshine Products+2.89%+8.32%+10.41%+33.39%+7.66%THTXTheratechnologies+1.28%+34.32%+22.87%+104.52%+123.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABEOAbeona Therapeutics3.9754 of 5 stars3.52.00.04.51.82.50.0ABUSArbutus Biopharma1.4422 of 5 stars3.50.00.00.00.02.50.6ARCTArcturus Therapeutics3.727 of 5 stars4.62.00.00.03.22.50.6NATRNature's Sunshine Products1.8253 of 5 stars2.53.00.00.02.72.50.0THTXTheratechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics 3.00Buy$19.25234.78% UpsideABUSArbutus Biopharma 3.00Buy$5.5075.16% UpsideARCTArcturus Therapeutics 3.11Buy$54.00304.19% UpsideNATRNature's Sunshine Products 3.00Buy$18.3314.44% UpsideTHTXTheratechnologies 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownLatest ARCT, ABUS, ABEO, NATR, and THTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025THTXTheratechnologiesJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/2/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform7/2/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$32.00 ➝ $35.006/3/2025NATRNature's Sunshine ProductsDA DavidsonSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.006/2/2025ABEOAbeona TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$19.005/28/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$32.005/16/2025ABEOAbeona TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $20.005/15/2025ABEOAbeona TherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/14/2025ARCTArcturus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$50.00 ➝ $45.005/13/2025ARCTArcturus TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/13/2025ARCTArcturus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$68.00 ➝ $66.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$3.50M84.05N/AN/A$1.01 per share5.69ABUSArbutus Biopharma$6.17M97.47N/AN/A$0.51 per share6.16ARCTArcturus Therapeutics$152.31M2.38N/AN/A$8.90 per share1.50NATRNature's Sunshine Products$454.36M0.65$1.28 per share12.48$8.71 per share1.84THTXTheratechnologies$85.87M1.70N/AN/A($0.55) per share-5.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics-$63.73M-$1.27N/AN/AN/AN/A-118.82%-52.48%8/11/2025 (Estimated)ABUSArbutus Biopharma-$69.92M-$0.41N/AN/AN/A-1,196.64%-75.51%-55.81%8/7/2025 (Estimated)ARCTArcturus Therapeutics-$80.94M-$2.53N/AN/AN/A-47.47%-27.41%-19.01%8/4/2025 (Estimated)NATRNature's Sunshine Products$7.70M$0.5330.23∞N/A2.22%6.98%4.63%8/6/2025 (Estimated)THTXTheratechnologies-$8.31M-$0.08N/A45.29N/A-4.18%N/A-0.37%7/9/2025 (Estimated)Latest ARCT, ABUS, ABEO, NATR, and THTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025ARCTArcturus Therapeutics-$1.11N/AN/AN/A$17.64 millionN/A5/15/2025Q1 2025ABEOAbeona Therapeutics-$0.35-$0.24+$0.11-$0.24N/AN/A5/14/2025Q1 2025ABUSArbutus Biopharma-$0.09-$0.13-$0.04-$0.13$2.54 million$1.76 million5/12/2025Q1 2025ARCTArcturus Therapeutics-$1.58-$0.52+$1.06-$0.52$25.64 million$29.38 million5/6/2025Q1 2025NATRNature's Sunshine Products$0.16$0.25+$0.09$0.25$109.39 million$113.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/AABUSArbutus BiopharmaN/AN/AN/AN/AN/AARCTArcturus TherapeuticsN/AN/AN/AN/AN/ANATRNature's Sunshine ProductsN/AN/AN/AN/AN/ATHTXTheratechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona Therapeutics0.274.904.90ABUSArbutus Biopharma0.046.016.01ARCTArcturus Therapeutics0.065.645.64NATRNature's Sunshine ProductsN/A2.411.50THTXTheratechnologiesN/A1.080.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%ABUSArbutus Biopharma43.79%ARCTArcturus Therapeutics94.54%NATRNature's Sunshine Products79.40%THTXTheratechnologiesN/AInsider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics5.40%ABUSArbutus Biopharma20.30%ARCTArcturus Therapeutics15.30%NATRNature's Sunshine Products5.60%THTXTheratechnologiesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona Therapeutics9051.16 million48.40 millionOptionableABUSArbutus Biopharma90191.53 million152.65 millionOptionableARCTArcturus Therapeutics18027.12 million22.97 millionOptionableNATRNature's Sunshine Products85018.46 million17.43 millionOptionableTHTXTheratechnologies14045.98 millionN/AOptionableARCT, ABUS, ABEO, NATR, and THTX HeadlinesRecent News About These CompaniesTheratechnologies: Beyond GLP-1s - Is Tesamorelin's Exit A Sign Of New Metabolic Opportunities?July 7 at 1:19 PM | seekingalpha.comTheratechnologies (NASDAQ:THTX) Stock Rating Lowered by Jones TradingJuly 5 at 2:01 AM | americanbankingnews.comFuture Pak to buy Theratechnologies for $254 millionJuly 4, 2025 | thepharmaletter.comTTheratechnologies Stock (NASDAQ:THTX), Insider Trading ActivityJuly 3, 2025 | benzinga.comTheratechnologies Inc. (THTX) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comTheratechnologies Stock Short Interest Report | NASDAQ:THTX - BenzingaJuly 3, 2025 | benzinga.comTheratechnologies shareholders should take the deal, Research Capital saysJuly 3, 2025 | cantechletter.comCTheratechnologies to be bought by CB Biotechnology for $254MJuly 3, 2025 | msn.comTheratechnologies to Announce Second Quarter 2025 Financial ResultsJuly 3, 2025 | globenewswire.comTheratechnologies' (THTX) Hold Rating Reaffirmed at Jones TradingJuly 3, 2025 | marketbeat.comTheratechnologies to be Acquired by Future Pak AffiliateJuly 2, 2025 | tipranks.comTheratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future PakJuly 2, 2025 | finance.yahoo.comTheratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future PakJuly 2, 2025 | globenewswire.comTheratechnologies Reports on its Annual Meeting of ShareholdersMay 29, 2025 | globenewswire.comTheratechnologies announces annual shareholder meetingMay 4, 2025 | uk.investing.comTheratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIVMay 2, 2025 | globenewswire.comTheratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 OfferApril 18, 2025 | seekingalpha.comIs Theratechnologies Inc. (THTX) the Best Rising Penny Stock to Buy According to Analysts?April 18, 2025 | msn.comTheratechnologies to further evaluate potential sale of the companyApril 16, 2025 | markets.businessinsider.comTheratechnologies Provides Update on Sale ProcessApril 15, 2025 | financialpost.comFTheratechnologies Provides Update on Sale ProcessApril 15, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARCT, ABUS, ABEO, NATR, and THTX Company DescriptionsAbeona Therapeutics NASDAQ:ABEO$5.75 -0.14 (-2.38%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$5.79 +0.04 (+0.70%) As of 07/7/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Arbutus Biopharma NASDAQ:ABUS$3.14 -0.10 (-3.09%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$3.16 +0.02 (+0.67%) As of 07/7/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.Arcturus Therapeutics NASDAQ:ARCT$13.36 -0.42 (-3.05%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$13.44 +0.08 (+0.60%) As of 07/7/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Nature's Sunshine Products NASDAQ:NATR$16.02 +0.43 (+2.76%) As of 07/7/2025 04:00 PM EasternNature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.Theratechnologies NASDAQ:THTX$3.17 -0.03 (-0.94%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$3.16 -0.02 (-0.47%) As of 07/7/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
